Mr. Vigodman, who’s served as Teva’s CEO for the past three years, will also leave his position on the company’s board of directors. Teva said the departure was a mutual agreement between the board and Mr. Vigodman, according to the report.
Yitzhak Peterburg, MD, PhD, will serve as interim president and CEO while the company looks for a permanent replacement. Dr. Peterburg has been Teva’s chairman since 2015.
Mr. Vigodman’s departure comes almost two month after Teva, along with five other generic drugmakers, was named in a lawsuit filed by 20 states alleging the companies conspired to fix prices of generic treatments.
“I believe that now is the right time for me to step down,” Mr. Vigodman said in a prepared statement. “It has been a privilege to lead Teva, and I am proud of all we have accomplished. I am confident that the company’s future is bright.”
More articles on supply chain:
Myan to settle class-action Provigil suit for $96.5M
Pharma turns to pay for performance pricing amid criticism on drug costs
New bill in California takes aim at drug coupons: 4 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
